AML over 60 yr
1. Secondary AML increasingly resistant to frontline chemo , worse RFS but not increased TRM
2. TP 53 mutated AML and MDS EB similar in outcomes
Subscribe to:
Post Comments (Atom)
-
Type 1 inhibitors good against TKD and ITD FLT3 ( ITD is the one associated with shorter DOR and higher relapse rates) Type 2 ( quizartinib ...
-
Frontline is platinum based chemo with or without bev. G ermline BRCA or HRD, negative - - Observation is ok, Niraparib cat 2A based on ...
-
1. Tafasitamab - CD 19 Ab: approved with lenalidomide for patients with R/R DLBCL ineligible for ASCT. median OS 3 yr. 2L, ineligible for...
No comments:
Post a Comment